{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Breast+Cancer&page=3", "query": { "condition": "Advanced or Metastatic Breast Cancer", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 588, "total_pages": 59, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Breast+Cancer&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Breast+Cancer&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T15:24:36.533Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03310957", "title": "Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "ladiratuzumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2018-02-27", "completion_date": "2024-09-30", "has_results": true, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-10-02T15:24:36.533Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310957" }, { "nct_id": "NCT06545331", "title": "Study of XB010 in Subjects With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors", "Esophageal Squamous Cell Cancer", "Head and Neck Squamous Cell Cancer", "NSCLC (Non-small Cell Lung Cancer)", "Hormone-receptor-positive Breast Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "XB010", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 396, "start_date": "2024-08-06", "completion_date": "2027-10-20", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-02T15:24:36.533Z", "location_count": 16, "location_summary": "Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06545331" }, { "nct_id": "NCT00634634", "title": "Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 52, "start_date": "2008-08-11", "completion_date": "2023-04-28", "has_results": true, "last_update_posted_date": "2023-11-09", "last_synced_at": "2026-10-02T15:24:36.533Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Voorhees Township", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00634634" }, { "nct_id": "NCT00369109", "title": "Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "biologic sample preservation procedure", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2006-02", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2013-04-08", "last_synced_at": "2026-10-02T15:24:36.533Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00369109" }, { "nct_id": "NCT00493636", "title": "1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accelerated Community Oncology Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2007-06", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-10-02T15:24:36.533Z", "location_count": 44, "location_summary": "Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00493636" }, { "nct_id": "NCT04991480", "title": "A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Breast Cancer" ], "interventions": [ { "name": "ART4215", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artios Pharma Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2021-09-13", "completion_date": "2025-12-24", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-10-02T15:24:36.533Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Orlando, Florida • New York, New York + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04991480" }, { "nct_id": "NCT01572727", "title": "A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "BKM120 matching placebo", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 416, "start_date": "2012-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-10-02T15:24:36.533Z", "location_count": 21, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Greenbrae", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01572727" }, { "nct_id": "NCT06120283", "title": "BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Breast Cancer", "Metastatic Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Hormone Receptor Positive Malignant Neoplasm of Breast", "HER2-negative Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer" ], "interventions": [ { "name": "BGB-43395", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Elacestrant", "type": "DRUG" }, { "name": "Anti-Diarrheal Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 433, "start_date": "2023-12-01", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-02T15:24:36.533Z", "location_count": 9, "location_summary": "Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120283" }, { "nct_id": "NCT07288359", "title": "Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced HR+/HER2- Breast Cancer", "Advanced CCNE1-amplified Solid Tumors", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "GVV858", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2025-12-29", "completion_date": "2031-05-09", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-02T15:24:36.533Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288359" }, { "nct_id": "NCT04432454", "title": "Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Lasofoxifene and abemaciclib (VERZENIO (R)).", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sermonix Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 29, "start_date": "2020-09-29", "completion_date": "2025-01-28", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-10-02T15:24:36.533Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Yuma, Arizona • Fountain Valley, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04432454" } ] }